Verteporfin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Verteporfin
Verteporfin.svg
Systematic (IUPAC) name
3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
Clinical data
Trade names Visudyne
AHFS/Drugs.com monograph
MedlinePlus a607060
Pregnancy cat. C (US)
Legal status -only (US)
Routes Intravenous
Identifiers
CAS number 129497-78-5 YesY
ATC code S01LA01
PubChem CID 5362420
DrugBank DB00460
ChemSpider 21106402 YesY
UNII 0X9PA28K43 YesY
KEGG D01162 YesY
ChEBI CHEBI:60775 YesY
ChEMBL CHEMBL2218885 N
Chemical data
Formula C41H42N4O8 
Mol. mass 718.794 g/mol
 N (what is this?)  (verify)

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.[1][2]

Verteporfin is also used off-label for the treatment of central serous retinopathy.[3]

Administration[edit]

Verteporfin is given intravenously, 15 minutes before laser treatment.[1]

Contraindications[edit]

Porphyria.[1]

Side effects[edit]

Most common side effects are blurred vision, headache, and local effects at the injection site. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.[1]

Interactions[edit]

None known. Verteporfin has no influence on the liver enzyme CYP3A4, which metabolises many pharmaceutical drugs.[1]

References[edit]

  1. ^ a b c d e Verteporfin monograph
  2. ^ Scott, L. J.; Goa, K. L. (2000). "Verteporfin". Drugs & aging 16 (2): 139–146; discussion 146–8. doi:10.2165/00002512-200016020-00005. PMID 10755329.  edit
  3. ^ Adelman, R.; Adelman, R. A. (2013). "Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy". Clinical Ophthalmology 7: 1867–1875. doi:10.2147/OPTH.S32177. PMC 3788817. PMID 24092965.  edit

External links[edit]